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 Patient: Female, 57
 Final Diagnosis: Meningeal carcinomatosis from breast cancer
 Symptoms: Seizures
 Medication: —
 Clinical Procedure: —
 Specialty: Oncology
 Objective: Unusual clinical course
 Background: Meningeal carcinomatosis is a rare complication in breast cancer patients. At present, there are no defined 
guidelines for its management. The efficacy of systemic treatment seems to depend on its ability to cross the 
blood-brain-barrier and its interaction with tumor vasculature. Metronomic chemotherapy is a known modal-
ity of drug administration able to inhibit tumor angiogenesis.
 Case Report: We present a case of symptomatic leptomeningeal carcinomatosis from breast cancer successfully treated with 
capecitabine. Based on the hypothesis that angiogenesis contributes to neoplastic meningitis, the patient was 
treated with a metronomic schedule that provided long-term clinical benefit with a very low toxicity profile.
 Conclusions: To assess the real impact of metronomic chemotherapy in patients with meninges involvement, a phase II 
study will be starting soon in our institution. A review of the literature concerning the management of menin-
geal carcinomatosis is also presented.
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Background
Meningeal carcinomatosis (MC) is a rare complication in can-
cer patients due to brain and/or spinal cord meninges involve-
ment. If left untreated, median survival is 4–6 weeks; if treat-
ed, median survival is 2–3 months [1]. About 2–5% of patients 
with breast cancer (BC) develop MC, usually late in the course 
of their metastatic disease [2]. Three methods are routine-
ly used to diagnose neoplastic meningitis: clinical signs and 
symptoms, cerebrospinal fluid cytology, and brain/spine mag-
netic resonance imaging (MRI). Treatment goals include im-
provement or stabilization of neurologic symptoms. Intrathecal 
therapy, radiotherapy, and systemic chemotherapy have been 
proposed, without clear survival benefit [3].
Capecitabine is a known anticancer drug used in the treat-
ment of advanced BC. Low-dose metronomic capecitabine was 
shown to induce disease control with a lower incidence of ad-
verse events compared with conventional maximum-tolerat-
ed-dose chemotherapy. This approach is known to enhance 
the anti-angiogenic activity of this agent [4].
Case Report
In June 2008, a 57-year-old post-menopausal woman was re-
ferred to our hospital because of a pathological fracture of 
the left arm. She was diagnosed with stage IV BC with multi-
ple bone and lung metastases. The biological characterization 
of disease revealed an invasive ductal carcinoma with hor-
monal receptors positive (estrogen receptor 100%, proges-
terone receptor 20%), human epidermal growth factor recep-
tor type 2 (HER2) negative, and high proliferative rate (MIB-1 
30%). The patient was started on first-line hormonal thera-
py with letrozole and zoledronic acid associated with pallia-
tive radiotherapy on the left arm and the spinal cord (D8–L1). 
Disease was stable until March 2012, when bone progression 
occurred, and a second-line hormonal therapy with Fulvestrant 
was commenced. In March 2014, serum cancer antigen 15-3 
(Ca15-3) and carcinoembryonic antigen (CEA) levels increased 
to 321 U/ml and 150 ng/ml, respectively. A spinal MRI con-
firmed bone progression, without visceral progression on CT 
scan. A third-line therapy with exemestane plus everolimus 
was proposed. In June 2014, the patient referred to our emer-
gency room due to a seizure. After a negative central nervous 
system (CNS) CT scan, a contrast-enhanced MRI of the brain 
and spinal cord was performed. It reveled larger contrast-en-
hancing leptomeningeal lesions (Figure 1). No bone progres-
sion or visceral disease were detected by CT scan. A signifi-
cant increase of Ca15.3 and CEA were also reported (Ca15.3 
758 U/ml, CEA 155 ng/ml). Cerebrospinal fluid analysis was not 
performed because of the poor compliance of the patient. The 
MC was diagnosed through radiological imaging and neuro-
logical symptoms. Based on the diagnosis of MC and consider-
ing the poor performance status of the patient, a metronomic 
schedule of capecitabine (500 mg 3 times a day continuous-
ly) was proposed. After the start of metronomic capecitabine, 
Ca15.3 and CEA levels gradually reduced and MRI performed 
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Figure 1.  (A) The contrast-enhanced T1-weighted MRI shows multiple and diffuse bone metastatic lesions that infiltrate dural tissue 
into the subarachnoid space. Thickened and irregular enhancement with surrounding edema is seen along frontal, left, and 
right parietal lobes. (B) Flair (fluid attenuated inversion-recovery) shows the erosive changes of the cortical margins of the 
cranial bone with masses involving the subarachnoid space.
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after 6 months of treatment showed reduction of the lepto-
meningeal lesions and tumor vasculature (Figure 2). Persisting 
bone and visceral stable disease was also reported on CT scan. 
The adverse effects of metronomic capecitabine were negligi-
ble. Leptomeningeal progression-free survival, at time of case 
reporting, was 23 months. No more seizures were reported, 
and the patient is still well and has good performance status.
Discussion
Despite new anticancer strategies developed in recent years, there 
has been no improvement in the treatment of MC [2]. Intrathecal 
chemotherapy has been proposed, but it requires invasive proce-
dures and its benefit has never been demonstrated in random-
ized clinical trials. Three drugs are used for intrathecal applica-
tion: methotrexate (MTX), AraC (DEPOCYTE®), and thiotepa. In a 
prospective controlled trial, DEPOCYTE® was compared to MTX 
in 61 patients with MC, with similar response rates [5]. A simi-
lar study [6] reported a significantly improved median time in-
terval to neurological progression for AraC. No prolonged surviv-
al or higher response rates have been shown from combination 
therapies (e.g., MTX + AraC) [7]. Focal radiotherapy to symp-
tomatic sites or bulky disease are usually used, but with con-
troversial results [3]. Concerning systemic treatment, the entire 
therapeutic success seems to depend on its ability to cross the 
blood-brain barrier (BBB). Although most of the drugs given sys-
temically have poor cerebrospinal fluid penetration, various stud-
ies have shown that in MC the BBB is more permeable. Agents 
most commonly used are temozolomide, BCNU, CCNU, topote-
can, lapatinib, trastuzumab, methotrexate, and capecitabine [3].
Capecitabine is an oral third-generation fluoropyrimidine car-
bamate. It is a prodrug converted by 3 enzymatic reactions 
to 5-fluorouracil [8]. Single-agent capecitabine demonstrated 
activity against BC progression with anthracyclines and tax-
anes, with a clinical response rate of 15–29%, stable disease 
in 31–46% of patients, and median overall survival of 10–15 
months [9,10]. The standard package insert recommends a 
starting dose of 2500 mg/mq twice daily for 14 days every 3 
weeks. Nevertheless, at the standard dose, capecitabine has a 
well-established toxicity profile: palmar-plantar erythrodyses-
thesia (PPE) ranging from 18% to 64%, grade 3 and 4 diarrhea 
in 5–19%, as well as stomatitis, nausea, and vomiting [8]. To 
reduce toxicity and improve the compliance to capecitabine, 
metronomic administration has been proposed, showing a 
median progression-free survival of 6.9 months and overall 
survival of 24.8 months in metastatic BC patients previously 
treated with anthracycline and taxane [11]. Worse outcomes 
have been reported in heavily pretreated metastatic BC pa-
tients [12]. The rationale for the metronomic schedule was 
the possibility to overcome drug resistance, targeting both 
tumor cells and tumor vasculature [13,14]. It well known that 
continuous low-dose capecitabine has anti-angiogenic action. 
Preclinical evidence showed that chronic administration of low-
dose capecitabine prevented effective recovery of the dam-
aged tumor vasculature [15]. Metronomic chemotherapy also 
induces the anti-angiogenic glycoprotein Thrombospondin-1 
(TSP1), which is endowed with further anti-tumor effects [16].
Preclinical and clinical studies highlighted the role of angiogen-
esis in the development of neoplastic meningitis. Groves et al. 
reported that elevated cerebrospinal fluid levels of VEGF are 
A B
Figure 2.  (A, B) The brain MRI performed after 6 months of metronomic capecitabine, confirming the diffuse bone and meningeal 
disease involvement, and showing initial response to the treatment and reduction in tumor vasculature.
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highly specific for the diagnosis of MC, and that VEGF expres-
sion is correlated with survival [17]. A study [18] showed a sig-
nificant decline in VEGF level after 2 and 6 months from base-
line among the patients with disease control, supporting the 
importance of angiogenesis in the development of MC.
In the literature, there are few reports of the efficacy of 
capecitabine in the treatment of MC [19–22], and none in pa-
tients treated with a metronomic schedule. Our case report is 
the first showing a long-term response in leptomeningeal me-
tastasis treated with metronomic capecitabine. Considering the 
reduction in tumor vasculature shown on RMN after 6 months 
of treatment, we hypothesized that the anti-angiogenic activ-
ity of metronomic capecitabine was the main mechanism re-
sponsible for long-term disease control.
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MC presents a poor prognosis. Currently available therapies are 
toxic and provide limited benefits. Metronomic capecitabine 
could be the treatment of choice to induce disease control, 
mainly due to interaction with tumor vasculature and inhibi-
tion of tumor angiogenesis. To assess the real impact of this 
metronomic treatment in patients with MC, a phase II study 
will be starting soon.
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